Increased expression of membrane TNF-α on activated peripheral CD8+ T cells in systemic lupus erythematosus

International Journal of Molecular Medicine

Volumn 17, Issue 5, 2006, Pages 875-879

  Horiuchi, Takahiko ^a   Morita, Chika ^a   Tsukamoto, Hiroshi ^a   Mitoma, Hiroki ^a   Sawabe, Takuya ^a   Harashima, Shin Ichi ^a   Kashiwagi, Yoichiro ^a   Okamura, Seiichi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Cytotoxic activity; Membrane tumor necrosis factor ; Systemic lupus erythematosus

Indexed keywords

MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR CELL LINE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750598093     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.5.875     Document Type: Article

References (29)

1. Vandenabeele P, Declerq W, Beyaert R and Fiers W: Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 5: 392-399, 1995.
2. Feldmann M and Maini RN: Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 19: 163-196, 2001.
3. Maury CP and Teppo AM: Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 32: 146-150, 1989.
4. Studnicka-Benke A, Steiner G, Petera P and Smolen JS: Tumor necrosis factor alpha and its receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35: 1067-1074, 1996.
5. Wilson AG, Gordon C, Di Diovine FS, De Vries N, Emery P, Van De Putte LB and Duff GW: A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 24: 191-195, 1994.
6. Rudwaleit M, Tikly M, Khamashta M, Gibson K, Klinke J, Hughes G and Wordsworth P: Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 23: 1725-1728, 1996.
7. Hajeer AH, Worthington J, Davies EJ, Hillarby MC, Poulton K and Ollier WE: TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens 49: 222-227, 1997.
8. Jacob CO and McDevitt HO: Tumor necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 331: 356-358, 1988.
9. Theofilopoulos AN and Lawson BR: Tumor necrosis factor and cytokines in murine lupus. Ann Rheum Dis 58: 149-155, 1999.
10. Gaffney P, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malmgren ML, Rohlf KE, Ockenden TC, Messner RP, King RA, Rich SS and Behrens TW: A genome-wide search for susceptibility genes in human systemic lupus erythematosus sibpair families. Proc Natl Acad Sci USA 95: 14875-14879, 1998.
11. Shai R, Quismorio Jr FP, Li L, Kwon O, Morrison J, Wallace DJ, Neuwelt CM, Brautbar C, Gauderman WJ and Jacob CO: Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 8: 639-644, 1999.
12. Komata T, Tsuchiya N, Matsushita M, Hagiwara K and Tokunaga K: Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens 53: 527-533, 1999.
13. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K and Niho Y: Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese. Molecular and functional analysis. Arthritis Rheum 44: 2819-2827, 2001.
14. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo A-M, Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R, Kumarajeewa TR, Cooper SM, Vella JP, Amos CI, Mulley J, Quane KA, Molloy MG, Ranki A, Powell RJ, Hitman GA, O'Shea JJ and Kastner DL: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97: 133-144, 1999.
15. Horiuchi T, Tsukamoto H, Mitoma H, Miyagawa H, Tamimoto Y, Yoshizawa S, Harada M, Hayashi K, Hashimura C, Oribe M and Okamura S: Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosis in Japanese. Int J Mol Med 14: 813-818, 2004.
16. Ida H, Kawasaki E, Miyashita T, Tanaka F, Kamachi M, Izumi Y, Huang M, Tamai M, Origuchi T, Kawakami A, Migita K, Motomura M, Yoshimura T and Eguchi K: A novel mutation (T61I) in the gene encoding tumor necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus. Rheumatology 43: 1292-1299, 2004.
17. Aringer M, Graninger WB, Steiner G and Smolen JS: Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus. An open-label study. Arthritis Rheum 50: 3161-3169, 2004.
18. Horiuchi T, Higuchi M, Harashima S, Sawabe T, Nishizaka H, Kojima T, Yoshizawa S, Niho Y and Nagasawa K: Membrane TNF-α-mediated signal transduction in T cell-B cell interactions. In: Molecular and Genetic Approaches to Diseases: Immunology, Hematology, Oncology. Niho Y (ed). Vol. 1. Kyushu University Press, Fukuoka, pp11-18, 1998.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N and Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277, 1982.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger Jr TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL and Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.
21. Blanco P, Pitard V, Viallard J-F, Taupin J-L, Pellegrin J-L and Moreau J-F: Increase in activated CD8+ T lymphocytes expressiong perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 52: 201-211, 2005.
22. Rus V, Zernetkina V, Puliaev R, Cudrici C, Mathai S and Via CS: Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin Immunol 117: 48-56, 2005.
23. Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, Tsukamoto H, Tahira T, Hayashi K, Fujita S and Niho Y: Outside-to-inside signal through the membrane TNF-α induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 166: 130-136, 2001.
24. Eissner G, Kolch W and Scheurich P: Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 15: 353-366, 2004.
25. Kirchner S, Boldt S, Kolch W, Haffner S, Kazak S, Janosch P, Holler E, Andreesen R and Eissner G: LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J Leukoc Biol 75: 324-331, 2004.
26. Decker T, Lohmann-Matthes ML and Gifford GE: Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138: 957-962, 1987.
27. Higuchi M, Nagasawa K, Horiuchi T, Oike M, Yasukawa M, Ito Y and Niho Y: Membrane tumor necrosis factor-α (TNF-α) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation: characterization of membrane TNF-α. Clin Immunol Immunopathol 82: 133-140, 1997.
28. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S and Harada M: Infliximab induce potent anti-inflammatory responses by outside-to- inside signals through transmembrane TNF-α. Gastroenterology 128: 376-392, 2005.
29. Herrera PL, Harlan DL and Vassalli P: A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc Natl Acad Sci USA 97: 279-284, 2000.